Analyst firms · Morgan Stanley · TNDM

Morgan Stanley TNDM price target and rating history

Tandem Diabetes Care Inc. (TNDM) · Health Care

Morgan Stanley rates Tandem Diabetes Care Inc. (TNDM) Equal-Weight with a $22 price target, as of its latest action on Mar 5, 2025. It has published 3 rating actions on TNDM since August 2024, including 1 upgrade and 1 downgrade. Across 12 firms with a TNDM price target in the last 12 months, the median target is $26.50.

Current rating
Equal-Weight
Price target
$22
Median target, all firms
$26.50
Actions on TNDM
3

Morgan Stanley price target on TNDM

$45$34$2220252026
Morgan Stanley price target on TNDM, each point a stated target, August 2024 to March 2025.

Every Morgan Stanley rating on TNDM

How other firms rate TNDM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
StifelBuy$26Nov 18, 2026
BarclaysEqual Weight$18Oct 7, 2026
CitigroupNeutral$20Sep 30, 2026
William BlairOutperformAug 21, 2026
UBSNeutral$18Jul 28, 2026
Deutsche BankHold$15.50Jun 23, 2026
Wells FargoOverweight$27Jun 1, 2026
The Benchmark CompanyHoldMay 12, 2026
Truist SecuritiesBuy$35Mar 19, 2026
Piper SandlerOverweight$33Mar 17, 2026
Lake StreetBuy$50Feb 23, 2026
BofA SecuritiesNeutral$30Feb 20, 2026
TD CowenBuy$25Jan 27, 2026
Robert W. BairdOutperform$30Dec 16, 2025

Questions about Morgan Stanley and TNDM

What is Morgan Stanley's price target for TNDM?
Morgan Stanley's latest stated price target for Tandem Diabetes Care Inc. (TNDM) is $22, from its action on Mar 5, 2025.
What is Morgan Stanley's rating on TNDM?
Morgan Stanley rates TNDM Equal-Weight, a neutral rating, as of Mar 5, 2025.
When did Morgan Stanley last change its view on TNDM?
On Mar 5, 2025, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $45 to $22.
How does Morgan Stanley's TNDM target compare with other analysts?
Across 12 firms with a TNDM price target in the last 12 months, the median target is $26.50.

More TNDM rating histories

All Morgan Stanley ratingsTNDM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.